The histone demethylase LSD1 (Lysine Specific Demethylase 1, also known as KDM1A) has been the focus of recent interest in view of its high-level expression in acute myeloid leukemia (AML) and a range of solid tumors, as well as encouraging pre-clinical and early phase clinical studies using candidate inhibitors [1–4]. Here, KDM1A is linked to acute myeloid leukemia.